Scopus Bio preps trials of gene-silencing immuno-oncology dr...

Scopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start clinical testing in lymphoma patients later this year.

Alnylam gets CHMP backing for second gene-silencing drug Giv...

Alnylam to file rare kidney disease drug after trial win

After years where RNA interference research was in the doldrums, Alnylam is on a roll and is preparing to file a rare kidney disease drug with the FDA, after two previous approvals.

Roche swoops on Dicerna’s gene-silencing hepatitis B drug

TMC’s inclisiran impresses at ESC, but will it surpass PCSK9...

Alnylam plunges after deaths in rare disease trial

Alnylam has been forced to abandon one of its most advanced 'RNA interference' drugs after it produced a worrying number of patient deaths in trials.